| Literature DB >> 23581945 |
Abstract
The tale of dabigatran sounds some cautionary notes about proper critical appraisal of new randomised controlled trials,care in deciding on the generalisability of results, judicious screening of patients and lessons about the politics around increasingly lucrative drugs. The old lesson of caveat utilitor still holds: let the user beware!Entities:
Mesh：
Substances：
Year: 2013 PMID： 23581945 DOI： 10.5694/mja12.10729
Source DB: PubMed Journal: Med J Aust ISSN： 0025-729X Impact factor: 7.738